Our Work
Latham & Watkins Advises Pi-Cardia in Partnership with Venus Medtech to Bring Leaflex(TM) Aortic Valve Technology to China
July 14, 2020
Bicoastal team represented Pi-Cardia in the licensing transaction.
Venus Medtech (Hangzhou) Inc., the leading transcatheter heart valve medical device player in China, and Pi-Cardia Ltd., a global leader in the development of non-implant catheter-based solutions for treating heart valve calcification, has announced a collaboration to bring Pi-Cardia's Leaflex™ technology to China. Pi-Cardia's Leaflex™ catheter performs mechanical scoring of valve calcification, restoring leaflets' mobility and improving valve hemodynamics.
Latham & Watkins LLP represented Pi-Cardia in the licensing transaction with a corporate team led by New York partner Nathan Ajiashvili and Bay Area partner Judith Hasko, with associate Maya Ziv.